Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam.
OBJECTIVE
To compare the efficacy of short-term parenteral prophylaxis with piperacillin/tazobactam (P/T) with long-term oral prophylaxis with ciprofloxacin in preventing infective complications after transrectal prostatic biopsy (TPB).


METHODS
Patients scheduled for TPB were randomized to receive P/T (2250 mg intramuscular) twice daily for 2 days (Group 1), or ciprofloxacin (500 mg orally) twice daily for 7 days (Group 2), beginning on the evening before the procedure in both groups. All patients received a 100-mL phosphate enema 3 h before TPB. Evaluation included self-recording of body temperature in the 3 days after TPB, and culture of mid-stream urine (MSU) samples taken before and 3 and 15 days after TPB. Patients with indwelling urethral catheters or taking antibiotics or immunosuppressive drugs were excluded, as were patients with positive MSU cultures before TPB.


RESULTS
Of the 138 evaluable patients, 72 received parenteral P/T and 66 oral ciprofloxacin. Bacteriuria (> 105 c.f.u./mL) after TPB occurred in two of 72 (2.8%) patients in Group 1 and in three of 66 (4.5%) patients in Group 2; this difference was not statistically significant (P > 0.1). However, of the five patients with bacteriuria, two were symptomatic and both were in Group 2. Pyrexia occurred in only one patient in Group 2 with symptomatic urinary tract infection, and required hospitalization. No other patient reported a body temperature openface> 37.5 degrees C or drug-related side-effects.


CONCLUSIONS
This prospective study showed that short-term prophylaxis with P/T was associated with a low rate of asymptomatic bacteriuria, requiring no further treatment, whereas although the rate was similar on long-term prophylaxis with ciprofloxacin patients required further treatment, with one needing hospitalization. We recommend short-term prophylaxis with P/T despite its disadvantages of cost and parenteral administration.
Cormio
L
L
Department of Urology, Di Venere Hospital, Bari-Carbonara, Italy.
Berardi
B
B
Callea
A
A
Fiorentino
N
N
Sblendorio
D
D
Zizzi
V
V
Traficante
A
A
D000890:Anti-Infective Agents / Q000008:administration & dosage; D019072:Antibiotic Prophylaxis / Q000379:methods*; D001424:Bacterial Infections / Q000517:prevention & control*; D001706:Biopsy / Q000009:adverse effects* / Q000379:methods; D002939:Ciprofloxacin / Q000008:administration & dosage; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010406:Penicillins / Q000008:administration & dosage; D010878:Piperacillin / Q000008:administration & dosage; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011469:Prostatic Diseases / Q000473:pathology; D000078142:Tazobactam; D020728:Transurethral Resection of Prostate / Q000379:methods
D000890:Anti-Infective Agents; D004791:Enzyme Inhibitors; D010406:Penicillins; D002939:Ciprofloxacin; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin